大理药业(603963.SH):2020年度净利预降70%-78%
格隆汇1月29日丨大理药业(603963.SH)发布2020年年度业绩预告,预计2020年年度实现归属于上市公司股东的净利润与上年同期(法定披露数据)相比,将减少950万元到1050万元,同比减少70%到78%。预计归属于上市公司股东的扣除非经常性损益的净利润与上年同期(法定披露数据)相比,将减少537万元到637万元,同比减少123%到146%。
公司产品以醒脑静注射液和参麦注射液为主,主要通过医院终端进行销售。2020年因新冠疫情在各地爆发的影响,各等级医院接诊量大幅下降,导致终端药品用量下降,从而公司经营业绩同比有较大幅度的下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.